ENABLE takes on Oxford antibiotic resistance programme

17.11.2016

The University of Oxford takes the next step in targeting antimicrobial resistance, with help of the results and hit compounds delivered by the European Lead Factory. The Oxford team, led by Professor Chris Schofield, has got the opportunity to collaborate with the European Gram-Negative Antibacterial...Read more

ENABLE takes on Oxford antibiotic resistance programme

17.11.2016

The University of Oxford takes the next step in targeting antimicrobial resistance, with help of the results and hit compounds delivered by the European Lead Factory. The Oxford team, led by Professor Chris Schofield, has got the opportunity to collaborate with the European Gram-Negative Antibacterial Engine (ENABLE) project to further progress this programme towards clinical development.

The Oxford team had the EU Lead Factory screen their potential target against the Joint European Compound Library of the then >300,000 compounds provided by the industry partners. The high throughput screen and initial triaging provided 50 qualified hits. Multiple series of compounds were validated through resynthesis, biochemical and biophysical profiling at the European Screening Centre site in Newhouse, complemented with ligand–protein crystallography and antimicrobial evaluation at University of Oxford. According to EU Lead Factory’s Phil Jones (University of Dundee) “close collaboration with the Oxford team resulted in highly potent and selective compounds with favourable physicochemical properties, less than 5 months after the initial hit list had been delivered.”

With these results Professor Schofield turned to ENABLE, a project funded through IMI with the mission to develop programmes against gram-negative pathogens to clinical trials.
Professor Chris Schofield stresses the importance of EU programmes such as ENABLE and the European Lead Factory in “transforming an almost impossible task for an individual academic group into a solid scientific and commercially viable pathway.”

Further information
European projects major boost for antibiotic programme from University of Oxford (press release).


Read less

Press Release: ELF wins award and delivers 50,000 new compounds

30.04.2015

The prestigious Bio-IT World Best Practices prize has been granted to the European Lead Factory (ELF) for its Honest Data Broker (HDB) implementation of the ScienceCloud platform from BIOVIA. ELF also announces the synthesis of >50,000 new high quality compounds based on public proposals....Read more

Press Release: ELF wins award and delivers 50,000 new compounds

30.04.2015

The prestigious Bio-IT World Best Practices prize has been granted to the European Lead Factory (ELF) for its Honest Data Broker (HDB) implementation of the ScienceCloud platform from BIOVIA. ELF also announces the synthesis of >50,000 new high quality compounds based on public proposals. These compounds were subsequently included in the Joint European Compound Library (JECL).

Andrew Pannifer from the University of Dundee and Herman van Vlijmen from Janssen led development of the HDB with BIOVIA. Andrew Pannifer said that winning the Best Practices prize in the Knowledge Management category brought official recognition to the ELF project’s achievements in designing and managing a unique Intellectual Property (IP) model: “Our custom implementation of ScienceCloud HDB is a core technology supporting the ELF project. It combines fine-grained permissions with efficient access to the vast range of chemistry and biology data it stores. Herman van Vlijmen said that HDB is a valuable research tool: “One of our key goals at the ELF has been to make sure that good science can be conducted while safeguarding IP interests.”

“Delivering collaboration and analysis capabilities with ScienceCloud in support of ELF’s Honest Data Broker application was a key goal”, said Mathew Hahn, senior vice president and chief technology officer at Dassault Systèmes-BIOVIA. “We are delighted to have won the Bio-IT World award with the ELF – particularly with the judges’ assessment that ‘ScienceCloud is the only platform in its class.’”

50,000 novel compounds added to the JECL

Professor Adam Nelson from the University of Leeds, and Chair of the Consortium's Library Selection Committee, said that new IT tools have also been developed to support the enhancement of the JECL: “The web-based submission tool built by ChemAxon has been instrumental in recruiting innovative chemistry proposals – with 550 library proposals already considered and new proposals coming in every month. Reaching 50,000 compounds successfully synthesised by consortium partners is a tremendous achievement at this stage of the project. ”

“Not only are we now a quarter of the way to our 200,000 public compound target, but the compounds themselves are proving to be very distinctive when compared with typical screening collections. They are much more three-dimensional, and they provide new areas of chemical space to be explored.”

 

Didier Roche, VP of Strategic Innovation, EDELRIS, said that a special Bioorganic & Medicinal Chemistry Symposium in Print is being published in May, containing 13 articles describing some of the synthetic methods and scaffolds used to expand JECL: “We are seeing very clear evidence that the output of the ELF is allowing us to explore uncharted areas. There are diverse chemical scaffolds, which are not commercially available or represented within the subset of the JECL contributed by the EFPIA companies. The growing JECL is a key asset to enable the identification of compounds that modulate a wide range of novel target classes.”

Irene Norstedt, IMI* Acting Executive Director, said, “The European Lead Factory is a wonderful example of how IMI makes it possible for big pharmaceutical companies and talented scientists in many other organisations to pool their resources, creating a unique and much-needed infrastructure. The European Lead Factory is already helping researchers across Europe to advance their drug discovery programmes, and so will ultimately deliver benefits for patients and society.”

The European Lead Factory was established to promote the discovery of novel lead compounds, suitable for subsequent optimization either to drug candidates or to high‐quality pharmacological tools for the experimental validation of targets. Following a pre-competitive innovation model, the starting point for the JECL was more than 330k compounds contributed from private chemical libraries of seven members of the European Federation of Pharmaceutical Industries and Associations (EFPIA): Bayer Pharma, AstraZeneca, Lundbeck, Janssen, Merck KGaA, Sanofi, and UCB.

An additional 200,000 novel compounds for inclusion in the JECL are being developed by participating academic institutions and SMEs in the European Lead Factory. A consortium of 30 partners from industry and academia conducts all project workflows. HDB enables secure sharing of chemistry and biology data, and of triaged compounds that show promising characteristics for research programmes.

 

For information about the European Lead Factory contact:

Hiliana Fienieg, Head of Marketing and Communications, TI Pharma

Tel: +31 71 332 2036

Mobile: +31 6 5179 8572

E-mail: hiliana.fienieg(at)tipharma.com

 

Catherine Brett, Communication and Events Manager, IMI

Tel: +32 2 541 8214 Mobile: +32 484 896227

E-mail: catherine.brett(at)imi.europa.eu

 

###

About the European Lead Factory

The European Lead Factory is a novel, open-innovation platform for drug discovery, managed by an international consortium of 30 partners and funded under the European Innovative Medicines Initiative (IMI). It has been designed to offer unrivalled opportunities to non-contractual public and private parties for the discovery of new drug lead molecules.

European academics and SMEs benefit from access to an ‘industry-like’ discovery platform that encourages active participation. The ultimate goal is to address neglected diseases including bacterial infections, psychiatric disorders and oncology.

Total project budget is around €196 million, with €80 million from the European Commission and €91 million of ‘in kind’ contributions from participating members of the European Federation of Pharmaceutical Industries and Associations (EFPIA). A further €25 million comes from non-EFPIA participants.

High quality biology targets and chemistry scaffolds are being sought to promote cutting-edge research, with the aim of moving quickly to development of high-quality drug lead molecules on an unprecedented scale. Submitters of promising targets can also choose to partner with EFPIA companies, accessing the resources and support needed to progress all the way to drug trials.

To take advantage of this opportunity, or for further information, please continue on our website.

*Innovative Medicines Initiative, Europe's largest public-private partnership (www.imi.europa.eu)

###

 

Project executive partners communicating on behalf of the European Lead Factory:

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of around EUR 20,0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries.

More information on Bayer HealthCare: www.healthcare.bayer.com.

 

About TI Pharma

Top Institute Pharma (TI Pharma), a non-profit organization, enables groundbreaking pharmaceutical research for the development of new medicines by establishing and managing international public-private partnerships. Within an open innovation model, scientists, the business world, patient organizations and others collaborate in frontrunner, multidisciplinary research aimed at improving the development of socially valuable medicines.

More information on TI Pharma: www.tipharma.com.

 

About Taros Chemicals

Taros, an independent and privately owned contract research company based in Dortmund, Germany, has been serving the needs of pharmaceutical, chemical, agrochemical and biotech companies since 1999. More than 8.000 synthesis, research and process chemistry projects have successfully been delivered to the ever growing global customer base. Taros operates state-of-the art lab facilities and employs a team of scientists (65% of whom hold post-graduate degrees in Chemistry) who are committed to supporting the diverse needs of its customers in efficient drug discovery, medicinal chemistry and classical synthetic chemistry. Being committed to supporting our global customer base, we have developed TarosGate®. TarosGate® is a unique software suite putting cost, time and chemistry information at a Project Leader’s finger tips - 24h/7 from anywhere in the world.

More information on Taros Chemicals: www.taros.de.

 

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is the world's largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, and this is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Innovative Medicines Initiative currently supports 40 projects, many of which are already producing impressive results. The projects all address major bottlenecks in drug development, and so will accelerate the development of safer and more effective treatments for patients.

More info on IMI: www.imi.europa.eu.

 

Note: For a full list of partners, please go to www.europeanleadfactory.eu/about/partners.

Download full press release.


Read less

Press Release: First results confirm drug discovery potential of the European Lead Factory

04.06.2014

Early confirmation of the drug-discovery potential of the European Lead Factory has emerged with delivery of the first two Qualified Hit Lists (QHLs). Launched in January 2013, the Innovative Medicines Initiative (IMI)-funded* project gives the entire European research community access to a unique,...Read more

Press Release: First results confirm drug discovery potential of the European Lead Factory

04.06.2014

Early confirmation of the drug-discovery potential of the European Lead Factory has emerged with delivery of the first two Qualified Hit Lists (QHLs).

Launched in January 2013, the Innovative Medicines Initiative (IMI)-funded* project gives the entire European research community access to a unique, high quality and extensive lead-like compound library, the Joint European Compound Library (JECL). The European Lead Factory also offers the cutting-edge infrastructure and expertise needed to screen against novel biological targets. This creates an outstanding opportunity to discover novel compounds, summarized in a so-called Qualified Hit List (QHL), for use either as pharmacological tools or as the starting points for drug discovery projects.

 

Progress has been rapid: in addition to programmes taking place within participating EFPIA members, the European Lead Factory has already accepted 26 biology target programmes from universities and small and medium-sized enterprises (SMEs) across Europe, culminating in the current delivery of the first two QHLs. The public-private nature of the initiative is illustrated by the fact that these hit lists go to the Netherlands Cancer Institute (NKI) and to a corporate partner in the project (UCB).

 

Huib Ovaa, professor and group leader in chemical biology at NKI said that industry-standard facilities are now available for the best ideas: "Access to the European Lead Factory has fast-forwarded our drug discovery programme in the field of oncology by several years. The lead-like nature of JECL compounds and the expertise and facilities provided by the European Lead Factory mean that our results are of very high quality. This QHL goes far beyond a simple list of primary hits and I'm looking forward to further exploring the outcomes of this programme."

 

Stan van Boeckel, Chief Scientific Officer of the Pivot Park Screening Centre in Oss, the Netherlands, emphasised the benefits of collaboration: "It's very exciting to work together with researchers from all over Europe to translate their innovative targets and ideas to our ultra-high throughput screening (uHTS) facilities, and to provide them with quality hits for a flying start in drug discovery."

 

Alongside the public target programme, industrial partners are also screening their own targets against the JECL. Jeremy Davis, Director of Medicinal Chemistry at UCB, said that this early hit list shows how important the European Lead Factory will be over the next few years: "For a highly challenging target we had taken the hits generated in-house as far as they could go. Access to the JECL has provided us with a list of highly interesting hit compounds and a second chance to develop lead molecules."

 

Targets submitted to and accepted by the European Lead Factory are screened against the JECL, which contains over 300,000 compounds from the previously inaccessible proprietary collections of seven major pharmaceutical companies. As part of the project, the JECL will be expanded until it contains up to 500,000 compounds, via crowdsourcing of chemical library ideas. From January 2014, a web portal has enabled the submission of both biology targets and external compound library proposals to the European Lead Factory. Chemical library proposals benefit from fixed monetary rewards if they lead to the addition of more than 50 compounds to the JECL. At the time of writing, 214 chemistry proposals have been submitted by public chemistry partners, and 52 libraries have been successfully validated, resulting in more than 12,000 compounds synthesized and ready for screening.

 

Biological target programme owners receive QHLs of up to 50 compounds that show activity against their target and also fulfil additional (de)selection criteria as set out collaboratively in the screening programme.

 

The UCB and NKI programmes will now progress to follow-up work, designed ultimately to generate drug candidates. UCB will conduct research in-house, while NKI will be using the facilities provided by the European Lead Factory that are able to deliver an Improved Hit List (IHL). Phil Jones, Director of the European Screening Centre, Newhouse, said that these facilities, together with the opportunity to collaborate on developing an IHL, are very valuable to public target contributors: "Working closely with the programme owners, we offer extensive support potentially including biophysical, biostructural and in vitro DMPK experiments to further characterise the hit compounds and establish structure-activity relationships. Using the QHL as a starting point, we will apply our medicinal chemistry expertise to identify important functional groups and explore how changes to those groups can provide the programme owner with compounds showing the best activity levels."

 

The European Lead Factory aims to accept and execute another 100 public programmes over the next four years. "By combining the innovation of academia, the agility of SMEs and the experience of pharma, the European Lead Factory is a true public-private partnership aiming to change the game of drug discovery in Europe," said Michel Goldman, Executive Director of the Innovative Medicines Initiative.

 

###

 

The European Lead Factory is a novel, open-innovation platform for drug discovery, managed by an international consortium of 30 partners and funded under the European Innovative Medicines Initiative (IMI). It has been designed to offer unrivalled opportunities to non-contractual public and private parties for the discovery of new drug lead molecules.

 

European academics and SMEs benefit from access to an 'industry-like' discovery platform that encourages active participation. The ultimate goal is to address neglected diseases including bacterial infections, psychiatric disorders and oncology.

 

Total project budget is around €196 million, with €80 million from the European Commission and €91 million of 'in kind' contributions from participating members of the European Federation of Pharmaceutical Industries and Associations (EFPIA). A further €25 million comes from non-EFPIA participants.

 

High quality biology targets and chemistry scaffolds are being sought to promote cutting-edge research, with the aim of moving quickly to development of high-quality drug lead molecules on an unprecedented scale. Submitters of promising targets can also choose to partner with EFPIA companies, accessing the resources and support needed to progress all the way to drug trials.

 

To take advantage of this opportunity, or for further information, see the website at www.europeanleadfactory.eu.

 

*Innovative Medicines Initiative, Europe's largest public-private partnership (www.imi.europa.eu)

 

 

Press contacts

 

Hiliana Fienieg, Head of Marketing and Communications, TI Pharma

Tel: +31 71 332 2036

Mobile: +31 6 5179 8572

E-mail: hiliana.fienieg(at)tipharma.com

 

Catherine Brett, Communication and Events Manager, IMI

Tel: +32 2 541 8214 Mobile: +32 484 896227

E-mail: catherine.brett(at)imi.europa.eu

 

Stephanie Bush, Account Manager, EMG

Tel: +31 164 317 036

Mobile: +31 657 778 253

E-mail: sbush(at)emg-pr.com

 

 

###

 

 

Project executive partners communicating on behalf of the European Lead Factory:

 

About Bayer HealthCare

 

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of €17.2 billion (2011), is one of the world's leading innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.

 

Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries.

 

More information on Bayer HealthCare: www.healthcare.bayer.com.

 

 

About TI Pharma

 

Top Institute Pharma (TI Pharma), a non-profit organization, enables groundbreaking pharmaceutical research for the development of new medicines by establishing and managing international public-private partnerships. Within an open innovation model, scientists, the business world, patient organizations and others collaborate in frontrunner, multidisciplinary research aimed at improving the development of socially valuable medicines.

 

More information on TI Pharma: www.tipharma.com.

 

 

About Taros Chemicals

 

Taros Chemicals, an independent and privately owned contract research company based in Dortmund, Germany, has been serving the needs of biotech, pharmaceutical and chemical companies since 1999. More than 6,000 research and process chemistry projects have been successfully delivered to a global customer base. Taros Chemicals runs state-of-the art lab facilities and employs a team of graduates (50% of whom hold PhD degrees in Chemistry) who are committed to supporting the diverse needs of its customers in efficient drug discovery and medicinal chemistry. Being committed to supporting customers in efficient drug discovery and medicinal chemistry initiatives, Taros developed the software suite "Taros Gate". Taros Gate is unique software that puts cost, time and chemistry information at a Project Leader's fingertips - 24/7 from anywhere in the world.

 

More information on Taros Chemicals: www.taros.de.

 

Note: For a full list of partners, please go to www.europeanleadfactory.eu.

 

 

About the Innovative Medicines Initiative

 

The Innovative Medicines Initiative (IMI) is the world's largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, and this is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Innovative Medicines Initiative currently supports 40 projects, many of which are already producing impressive results. The projects all address major bottlenecks in drug development, and so will accelerate the development of safer and more effective treatments for patients.

 

More info on IMI: www.imi.europa.eu.

 

Download PDF


Files:
TIPPR002EN0614_European_Lead_Factory_02.pdf482 K
Read less

Launch of the European Lead Factory - Press release

07.02.2013

€196 million pan-European drug discovery platform launchedLarge pharmaceutical companies join forces with small and medium-sized enterprises (SMEs) and academia in an IMI-supported public private partnership (PPP) to enhance early drug discovery and so address the ever-increasing need for innovative...Read more

Launch of the European Lead Factory - Press release

07.02.2013

€196 million pan-European drug discovery platform launched
Large pharmaceutical companies join forces with small and medium-sized enterprises (SMEs) and academia in an IMI-supported public private partnership (PPP) to enhance early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs

Brussels, Belgium & Leiden, the Netherlands, 7 February 2013

The European Lead Factory, a novel platform for innovative drug discovery, was launched today by an international consortium of 30 partners. This partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented opportunities for the discovery of new medicines by providing public partners with an ‘industry-like’ discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

This will be made possible in part through access to an exceptional collection of small molecules. Part of this collection will be contributed by pharmaceutical companies, and the other part will be a newly synthesized compound collection built by the SMEs and academic institutions using the integrated knowledge of all consortium partners and through open innovation and crowd sourcing. Screening of this compound collection will be performed within the pharmaceutical companies and by a newly-established European Screening Centre. Stakeholders, including patient organisations and global health initiatives, are invited to contribute their knowledge and networks to the consortium to elevate the outcome of the early drug discovery process and to be part of the establishment of a new sustainable platform for early drug discovery.

Pharmaceutical companies have vast libraries of compounds which can be screened in the hunt for potential medicines. Usually, access to these compound libraries is highly restricted. As part of the European Lead Factory, the 7 participating pharmaceutical companies will contribute at least 300 000 chemical compounds from their corporate chemical collections. A library of an estimated additional 200 000 novel compounds will be developed jointly by academia and SMEs. Together, the two libraries will form a Joint European Compound Collection consisting of up to half a million compounds that will be accessible to all project partners and to public organisations offering promising new targets for drug discovery screening. These target proposals will be selected through competitive calls.

An equally important part of the European Lead Factory is the European Screening Centre, which will assist public contributors of novel targets in the development of tests amenable to the requirements of industrialised screening methodology. Both the sites in Scotland and the Netherlands will run state of the art facilities for compound logistics and high throughput screening to respectively handle the 500 000-strong compound library and to evaluate new compounds that are active against the novel targets. 

The total budget for the project amounts to around €196 million. Of this, €80 million comes from the European Commission’s Seventh Framework Programme for Research (FP7), and €91 million is provided as in kind contributions from the participating companies that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The remaining €25 million comes from other contributions from the non-EFPIA participants.

If the project proves successful during its initial five year funding period, the European Screening Centre and the teams of SMEs and academic institutions aim for a sustainable role in drug discovery and the future growth of drug development in Europe.

IMI Executive Director Michel Goldman commented: ‘IMI is very excited by the launch of the European Lead Factory. This unique project is an excellent example of how a public-private partnership can transform the way in which the pharmaceutical sector identifies new medicines. For the first time, it will give European researchers unprecedented access to industry chemical collections and facilitate the translation of their findings into actual treatments for patients. This project will not only advance the chances of success in the discovery of new medicines by European researchers, but also add value by building research capacity in Europe.’

Hanno Wild, Senior Vice President and Head of Candidate Generation & Exploration at Project Coordinator Bayer HealthCare Global Drug Discovery, says: ‘The European Lead Factory is an outstanding example of a project in which public-private partnerships enable collaborative drug discovery. The platform brings together academia and industry as well as small and medium enterprises in a unique partnership aiming to discover innovative medicines. Bayer is committed to further develop this novel platform by providing decades of experience in drug development. The joint efforts of the consortium will support drug discovery and hopefully generate new therapies for patients.’

The Netherlands-based non-profit TI Pharma will facilitate the governance of this new project and is responsible for the scientific management of the screening centre. Scientific Director of TI Pharma and Head of Screening of the European Lead Factory Ton Rijnders: ‘Establishing this public private partnership brings unprecedented opportunities to develop a sustainable ground breaking drug discovery platform based on superior input and output by connecting top notch science, decades of experience in drug discovery and development and the agility of SMEs.’

Dimitrios Tzalis, CEO of Taros Chemicals and Head of the European consortium’s chemistry effort, affirms: ‘The experience of creating an unparalleled drug discovery platform consisting of leading European SMEs and academia has been very exciting and compelling, to say the least. This platform of knowledge and experience, based on novel chemistry and innovative targets will be fortified by the pharmaceutical industry’s expansive knowledge in drug development, resulting in a giant surge forward in drug development.’

Notes to Editors

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.’

More information: http://www.imi.europa.eu/content/european-lead-factory

Project partners

EFPIA companies

Bayer Pharma AG, Germany

AstraZeneca AB, Sweden

H. Lundbeck A/S, Denmark

Janssen Pharmaceutica NV, a Pharmaceutical Company of Johnson & Johnson, Belgium

Merck KGaA, Germany

Sanofi, Germany

UCB Pharma SA, Belgium

 

Universities, research organisations, public bodies, non-profit groups

Foundation Top Institute Pharma (Stichting Top Instituut Pharma), the Netherlands

Leiden University, the Netherlands

Max Planck Gesellschaft zur Förderung der Wissenschaften E.V., Germany

Radboud University Nijmegen, the Netherlands

Stichting Het Nederlands Kanker Instituut, the Netherlands

Technical University of Denmark, Denmark

Universität Duisburg-Essen, Germany

University of Dundee, UK

University of Groningen, the Netherlands

University of Leeds, UK

University of Nottingham, UK

University of Oxford, UK

VU-University Amsterdam, the Netherlands

 

SMEs

BioCity Scotland Ltd, UK

ChemAxon, Hungary

Edelris S.A.S, France

GABO:mi Gesellschaft fur Ablauforganisation:Milliarium Mbh & Co Kg, Germany

Lead Discovery Center GmbH, Germany

Mercachem B.V., the Netherlands

Pivot Park Screening Centre B.V, the Netherlands

Sygnature Discovery Limited, UK

Syncom, the Netherlands

Taros Chemicals GmbH & Co KG, Germany

 

Press contacts

Catherine Brett, Communication and Events Manager, IMI
Tel: +32 2 541 8214 - Mobile: +32 484 896227
E-mail: catherine.brett(at)imi.europa.eu

Elianne Hoving, Head of Marketing and Communications, TI Pharma
Tel: +31 71 332 2036 - Mobile: +31 6 5179 8572
E-mail: elianne.hoving(at)tipharma.com

 

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is the world’s largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, and this is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Innovative Medicines Initiative currently supports 40 projects, many of which are already producing impressive results. The projects all address major bottlenecks in drug development, and so will accelerate the development of safer and more effective treatments for patients.

More info on IMI: www.imi.europa.eu

 

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of €17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries.

More information on Bayer HealthCare: www.healthcare.bayer.com

 

About TI Pharma

Top Institute Pharma (TI Pharma), a non-profit organization, enables groundbreaking pharmaceutical research for the development of new medicines by establishing and managing international public-private partnerships. Within an open innovation model, scientists, the business world, patient organizations and others collaborate in frontrunner, multidisciplinary research aimed at improving the development of socially valuable medicines.

More information on TI Pharma: www.tipharma.com

About Taros Chemicals

Taros Chemicals, an independent and privately owned contract research company based in Dortmund, Germany, has been serving the needs of biotech, pharmaceutical and chemical companies since 1999. More than 6.000 synthesis, research and process chemistry projects have successfully been delivered to the ever since growing global customer base. Taros Chemicals runs state-of-the art lab facilities and employs a team of graduates (50% of whom hold post-graduate degrees in Chemistry) who are committed to supporting the diverse needs of its customers in efficient drug discovery and medicinal chemistry,. Being committed to supporting our customers in efficient drug discovery and medicinal chemistry initiatives, we have developed Taros Gate. Taros Gate is a unique software suite putting cost, time and chemistry information at a Project Leader’s finger tips - 24h/7 from anywhere in the world.

More information on Taros Chemicals: www.taros.de

 


Read less